The Market Reports

Index

1 Checkpoint Inhibitors for Treating Cancer Market Overview
1.1 Product Overview and Scope of Checkpoint Inhibitors for Treating Cancer
1.2 Checkpoint Inhibitors for Treating Cancer Segment by Type
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Checkpoint Inhibitors for Treating Cancer Segment by Application
1.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Comparison by Application: (2021-2027)
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts
1.4.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2016-2027
1.4.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2016-2027
1.4.3 Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2016 Versus 2021 Versus 2027

2 Checkpoint Inhibitors for Treating Cancer Market Competition by Manufacturers
2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturers (2016-2021)
2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Checkpoint Inhibitors for Treating Cancer Manufacturing Sites, Area Served, Product Type
2.5 Checkpoint Inhibitors for Treating Cancer Market Competitive Situation and Trends
2.5.1 Checkpoint Inhibitors for Treating Cancer Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Checkpoint Inhibitors for Treating Cancer Players Market Share by Revenue
2.5.3 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario by Region
3.1 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.3.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country
3.3.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.4.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country
3.4.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Region
3.5.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region
3.5.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.6.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country
3.6.2 Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.7.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country
3.7.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Checkpoint Inhibitors for Treating Cancer Historic Market Analysis by Type
4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2016-2021)
4.3 Global Checkpoint Inhibitors for Treating Cancer Price by Type (2016-2021)

5 Global Checkpoint Inhibitors for Treating Cancer Historic Market Analysis by Application
5.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
5.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2016-2021)
5.3 Global Checkpoint Inhibitors for Treating Cancer Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Bristol-Myers Squibb(BMS)
6.1.1 Bristol-Myers Squibb(BMS) Corporation Information
6.1.2 Bristol-Myers Squibb(BMS) Description and Business Overview
6.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Portfolio
6.1.5 Bristol-Myers Squibb(BMS) Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Merck Checkpoint Inhibitors for Treating Cancer Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Roche Checkpoint Inhibitors for Treating Cancer Product Portfolio
6.3.5 Roche Recent Developments/Updates

7 Checkpoint Inhibitors for Treating Cancer Manufacturing Cost Analysis
7.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
7.4 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Checkpoint Inhibitors for Treating Cancer Distributors List
8.3 Checkpoint Inhibitors for Treating Cancer Customers

9 Checkpoint Inhibitors for Treating Cancer Market Dynamics
9.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
9.2 Checkpoint Inhibitors for Treating Cancer Growth Drivers
9.3 Checkpoint Inhibitors for Treating Cancer Market Challenges
9.4 Checkpoint Inhibitors for Treating Cancer Market Restraints

10 Global Market Forecast
10.1 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Checkpoint Inhibitors for Treating Cancer by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Checkpoint Inhibitors for Treating Cancer by Type (2022-2027)
10.2 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Checkpoint Inhibitors for Treating Cancer by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Checkpoint Inhibitors for Treating Cancer by Application (2022-2027)
10.3 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Checkpoint Inhibitors for Treating Cancer by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Checkpoint Inhibitors for Treating Cancer by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Comparison by Application (2021-2027)
Table 3. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Covered in This Study
Table 5. Global Checkpoint Inhibitors for Treating Cancer Sales (g) of Key Manufacturers (2016-2021)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Checkpoint Inhibitors for Treating Cancer Average Price (US$/mg) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Checkpoint Inhibitors for Treating Cancer Manufacturing Sites and Area Served
Table 11. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2016-2021) & (g)
Table 16. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2016-2021)
Table 17. Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 19. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 20. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 22. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 23. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 24. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2016-2021) & (g)
Table 27. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2016-2021)
Table 30. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 31. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 32. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 35. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2016-2021)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) by Type (2016-2021)
Table 41. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2016-2021)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Price (US$/mg) by Type (2016-2021)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2016-2021)
Table 44. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
Table 45. Global Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) by Application (2016-2021)
Table 46. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2016-2021)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Price (US$/mg) by Application (2016-2021)
Table 48. Bristol-Myers Squibb(BMS) Corporation Information
Table 49. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 50. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million US$), Price (US$/mg) and Gross Margin (2016-2021)
Table 51. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product
Table 52. Bristol-Myers Squibb(BMS) Recent Developments/Updates
Table 53. Merck Corporation Information
Table 54. Merck Description and Business Overview
Table 55. Merck Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million US$), Price (US$/mg) and Gross Margin (2016-2021)
Table 56. Merck Checkpoint Inhibitors for Treating Cancer Product
Table 57. Merck Recent Developments/Updates
Table 58. Roche Corporation Information
Table 59. Roche Description and Business Overview
Table 60. Roche Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million US$), Price (US$/mg) and Gross Margin (2016-2021)
Table 61. Roche Checkpoint Inhibitors for Treating Cancer Product
Table 62. Roche Recent Developments/Updates
Table 63. Production Base and Market Concentration Rate of Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 66. Checkpoint Inhibitors for Treating Cancer Customers List
Table 67. Checkpoint Inhibitors for Treating Cancer Market Trends
Table 68. Checkpoint Inhibitors for Treating Cancer Growth Drivers
Table 69. Checkpoint Inhibitors for Treating Cancer Market Challenges
Table 70. Checkpoint Inhibitors for Treating Cancer Market Restraints
Table 71. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2022-2027) & (g)
Table 72. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Type (2022-2027)
Table 73. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 74. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Type (2022-2027)
Table 75. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2022-2027) & (g)
Table 76. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2022-2027)
Table 77. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 78. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Application (2022-2027)
Table 79. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2022-2027) & (g)
Table 80. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Region (2022-2027)
Table 81. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 82. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Region (2022-2027)
Table 83. Research Programs/Design for This Report
Table 84. Key Data Information from Secondary Sources
Table 85. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Checkpoint Inhibitors for Treating Cancer
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2020 & 2027
Figure 3. PD-1 Inhibitors Product Picture
Figure 4. PD-L1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2020 & 2027
Figure 7. Melanoma Treatment
Figure 8. Bladder Cancer Treatment
Figure 9. Other
Figure 10. Global Checkpoint Inhibitors for Treating Cancer Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market Size 2016-2027 (US$ Million)
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Sales 2016-2027 (g)
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 14. Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturers in 2020
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers in 2020
Figure 16. The Global 5 and 10 Largest Checkpoint Inhibitors for Treating Cancer Players: Market Share by Revenue in 2020
Figure 17. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2016-2021)
Figure 19. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2020
Figure 20. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2016-2021)
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2020
Figure 22. U.S. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. France Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. U.K. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. South Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. India Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. China Taiwan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Indonesia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Thailand Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Malaysia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Argentina Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. UAE Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Type (2016-2021)
Figure 45. Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Application (2016-2021)
Figure 46. Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Application in 2020
Figure 47. Revenue Share of Checkpoint Inhibitors for Treating Cancer by Application (2016-2021)
Figure 48. Revenue Share of Checkpoint Inhibitors for Treating Cancer by Application in 2020
Figure 49. Manufacturing Cost Structure of Checkpoint Inhibitors for Treating Cancer
Figure 50. Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
Figure 51. Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed